143 related articles for article (PubMed ID: 18598765)
1. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
[TBL] [Abstract][Full Text] [Related]
2. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
Ke Y; Labrie F; Gonthier R; Simard JN; Bergeron D; Martel C; Vaillancourt M; Montesino M; Lavoie L; Archer DF; Balser J; Moyneur E;
J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
[TBL] [Abstract][Full Text] [Related]
4. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
Martel C; Labrie F; Archer DF; Ke Y; Gonthier R; Simard JN; Lavoie L; Vaillancourt M; Montesino M; Balser J; Moyneur É;
J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
6. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
[TBL] [Abstract][Full Text] [Related]
7. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
Labrie F; Martel C; Bérubé R; Côté I; Labrie C; Cusan L; Gomez JL
J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
[TBL] [Abstract][Full Text] [Related]
8. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
Labrie F; Martel C
Horm Mol Biol Clin Investig; 2017 Feb; 29(2):39-60. PubMed ID: 27997350
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.
Labrie F; Bélanger A; Labrie C; Candas B; Cusan L; Gomez JL
J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):57-69. PubMed ID: 17627814
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat.
Berger L; El-Alfy M; Labrie F
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):67-80. PubMed ID: 18242978
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
[TBL] [Abstract][Full Text] [Related]
12. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
13. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.
Labrie F; Diamond P; Cusan L; Gomez JL; Bélanger A; Candas B
J Clin Endocrinol Metab; 1997 Oct; 82(10):3498-505. PubMed ID: 9329392
[TBL] [Abstract][Full Text] [Related]
14. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
15. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
Barton DL; Shuster LT; Dockter T; Atherton PJ; Thielen J; Birrell SN; Sood R; Griffin P; Terstriep SA; Mattar B; Lafky JM; Loprinzi CL
Support Care Cancer; 2018 Apr; 26(4):1335-1343. PubMed ID: 29164377
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of DHEA in postmenopausal women following percutaneous administration.
Labrie F; Bélanger A; Bélanger P; Bérubé R; Martel C; Cusan L; Gomez J; Candas B; Chaussade V; Castiel I; Deloche C; Leclaire J
J Steroid Biochem Mol Biol; 2007 Feb; 103(2):178-88. PubMed ID: 17084625
[TBL] [Abstract][Full Text] [Related]
17. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
Ke Y; Gonthier R; Simard JN; Archer D; Lavoie L; Martel C; Vaillancourt M; Labrie F
Horm Mol Biol Clin Investig; 2015 Dec; 24(3):117-29. PubMed ID: 26509785
[TBL] [Abstract][Full Text] [Related]
18. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Martel C; Balser J
Gynecol Endocrinol; 2010 Jul; 26(7):524-32. PubMed ID: 20459349
[TBL] [Abstract][Full Text] [Related]
19. Science of intracrinology in postmenopausal women.
Labrie F; Bélanger A; Pelletier G; Martel C; Archer DF; Utian WH
Menopause; 2017 Jun; 24(6):702-712. PubMed ID: 28098598
[TBL] [Abstract][Full Text] [Related]
20. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
